ArticleJournal of cellular and molecular medicine2025
High Expression of IGSF10 Confers an Inhibitory Effect on the Progression of Lung Adenocarcinoma.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of immune cell crosstalk and signaling pathways in the pathogenesis of pulmonary fibrosis.Molecular biology reports · 2026Review
- High Expression of IGSF10 Confers an Inhibitory Effect on the Progression of Lung Adenocarcinoma.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide. Unlike conventional treatments, the targeted therapies or emerging immunotherapies have shown significant advantages in the management of advanced lung cancer. Therefore, exploring novel predictive biomarkers or therapeutic targets is still of far-reaching significance for the future treatment of lung cancer. This study revealed that low expression of IGSF10, an important member of the immunoglobulin superfamily, significantly correlates with poor overall survival of lung adenocarcinoma (LUAD) patients and strong tumorigenic capacity of LUAD cells. Mechanistically, high expression of IGSF10 can inhibit the epithelial-mesenchymal transition of LUAD cells via p53-triggering ferroptosis and impede G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.